Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology

Standard of Care and Treatment Strategies for MPNs

At a Glance

MPN treatment focuses on preventing blood clots and managing symptoms. Standard care involves keeping hematocrit below 45% in PV, using medications like hydroxyurea or interferons to control blood counts, and prescribing specific JAK inhibitors for myelofibrosis based on your unique lab results.

Treatment for myeloproliferative neoplasms (MPNs) is not “one size fits all.” Because these conditions are often chronic, the goal of treatment is twofold: to prevent dangerous complications like blood clots and to manage symptoms that interfere with your daily life [1][2].

Managing Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

In PV and ET, the primary concern is the thickness of the blood, which increases the risk of thrombosis (blood clots). Standard care follows these pillars:

  • Aspirin: Almost all patients take low-dose aspirin to help keep blood from sticking together [1].
  • Phlebotomy (PV only): This is the process of removing blood (similar to a blood donation) to thin it out. The gold standard target for every PV patient is a hematocrit (Hct) level below 45% (though some specialists aim for <42% in women) [3][4]. Research shows that staying below this number significantly reduces the risk of cardiovascular death and major clots [5][6].
  • Cytoreductive Therapy: These are medications used to lower blood counts when phlebotomy and aspirin aren’t enough, or if a patient is considered “high risk” (typically age 60+ or a history of clots) [1][7].
    • Hydroxyurea: A standard first-line daily pill that effectively lowers cell counts. Importantly, hydroxyurea can significantly increase your risk for non-melanoma skin cancers, making aggressive sun protection and regular dermatology checks mandatory [8].
    • Anagrelide: A specific pill used primarily for ET to lower platelet counts when other treatments aren’t tolerated or effective [1].
    • Pegylated Interferons (e.g., ropeginterferon-alfa-2b): An injectable medication that can also be used as first-line therapy. Unlike other treatments, interferons may have the potential to slow the underlying progression of the disease in some patients [9][10].

A Note on Family Planning: Because MPNs often affect younger patients, family planning is a crucial conversation. Hydroxyurea and anagrelide are generally unsafe during pregnancy and can cause birth defects, whereas interferons are considered safer options if you are trying to conceive [1].

Managing Myelofibrosis (PMF)

Treatment for myelofibrosis focuses more on reducing the size of an enlarged spleen and relieving systemic symptoms like night sweats and bone pain [11]. The choice of medication often depends on your specific blood counts:

The JAK Inhibitor “Decision Tree”

If your doctor recommends a JAK inhibitor (medications that block the overactive signaling pathway), the specific drug chosen usually depends on “if-then” scenarios based on your lab results:

  • If you have a normal platelet count: Ruxolitinib is typically the first-line standard of care for reducing spleen size and symptoms [11][12].
  • If Ruxolitinib isn’t working or isn’t tolerated: Fedratinib is an established second-line option [13][14].
  • If you have very low platelets (<50,000/µL): Pacritinib is specifically indicated for patients with severe thrombocytopenia (low platelets), a group that often cannot safely take other JAK inhibitors [15][16].
  • If you have significant anemia: Momelotinib is a newer option that helps reduce spleen size while potentially improving hemoglobin levels and reducing the need for blood transfusions [17][18].

Note that JAK inhibitors can suppress your immune system, increasing your risk for viral infections like shingles, so your doctor may recommend vaccines before starting [11].

Recognizing Substandard Care

You should feel empowered to ask questions if your treatment plan does not align with these established standards. For example, if you have PV and your hematocrit is consistently above 45%, or if you have myelofibrosis with very low platelets but are being prescribed a drug known to lower them further, a second opinion from an MPN specialist may be beneficial [3][15].

Back to Home Page

Common questions in this guide

What is the target hematocrit level for polycythemia vera (PV) patients?
The standard goal for patients with polycythemia vera is to keep the hematocrit level below 45% through phlebotomy or medication. Some specialists may aim for below 42% in women. Maintaining these levels significantly reduces the risk of dangerous blood clots.
Are MPN medications safe to take during pregnancy?
Hydroxyurea and anagrelide are generally not safe during pregnancy because they can cause birth defects. If you are planning a family, your doctor may recommend pegylated interferons, which are typically considered safer treatment options.
How do doctors choose which JAK inhibitor to use for myelofibrosis?
The choice of JAK inhibitor depends heavily on your specific blood test results. Ruxolitinib is usually the first choice, but pacritinib is used for very low platelets, momelotinib for significant anemia, and fedratinib if the first-line treatment stops working.
Does taking hydroxyurea increase my risk for other cancers?
Yes, taking hydroxyurea can significantly increase your risk of developing non-melanoma skin cancers. Patients taking this medication should use strict sun protection and schedule regular skin checks with a dermatologist.
What are the main goals of treatment for myeloproliferative neoplasms?
Because MPNs are chronic conditions, treatment focuses on two main goals: preventing dangerous complications like blood clots, and managing symptoms like fatigue, enlarged spleen, and bone pain that interfere with your daily life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my current hematocrit target strictly below 45%, and how often will we check it to ensure we are meeting that goal?
  2. 2.Am I a candidate for Interferon (like ropeginterferon-alfa-2b) instead of Hydroxyurea, and what are the long-term benefits of each?
  3. 3.Based on my platelet count and hemoglobin levels, which JAK inhibitor is the most appropriate starting point for me?
  4. 4.If my symptoms or blood counts don't improve on my current medication, what is the 'Plan B' (second-line therapy)?
  5. 5.Do I have any 'high-risk' features, like a history of blood clots or being over 60, that should change my treatment intensity?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Contemporary approach to essential thrombocythemia and polycythemia vera.

    Aruch D, Mascarenhas J

    Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

    PMID: 26717193
  2. 2

    NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

    Mesa RA, Jamieson C, Bhatia R, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(10)):1193-1207.

    PMID: 28982745
  3. 3

    Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera.

    Tashi T

    Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2022; (39(Suppl 2)):S43-S46 doi:10.12788/fp.0243.

    PMID: 35929004
  4. 4

    Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data.

    Parasuraman S, Yu J, Paranagama D, et al.

    Annals of hematology 2019; (98(11)):2533-2539 doi:10.1007/s00277-019-03793-w.

    PMID: 31552445
  5. 5

    Thromboembolic events in polycythemia vera.

    Griesshammer M, Kiladjian JJ, Besses C

    Annals of hematology 2019; (98(5)):1071-1082 doi:10.1007/s00277-019-03625-x.

    PMID: 30848334
  6. 6

    A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.

    Barbui T, Vannucchi AM, Finazzi G, et al.

    American journal of hematology 2017; (92(11)):1131-1136 doi:10.1002/ajh.24851.

    PMID: 28699191
  7. 7

    Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.

    Gangat N, Tefferi A

    American journal of hematology 2021; (96(3)):354-366 doi:10.1002/ajh.26067.

    PMID: 33296529
  8. 8

    Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival.

    Larsson AE, Renlund H, Andréasson B, et al.

    European journal of haematology 2026; (116(5)):545-557 doi:10.1111/ejh.70113.

    PMID: 41531010
  9. 9

    Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials

    Gisslinger H

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2023; (40(4)):266-268 doi:10.4274/tjh.galenos.2023.2023.0419.

    PMID: 38050364
  10. 10

    Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.

    Edahiro Y, Ohishi K, Gotoh A, et al.

    International journal of hematology 2022; (116(2)):215-227 doi:10.1007/s12185-022-03341-9.

    PMID: 35430707
  11. 11

    Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.

    Butler LA, Forsyth C, Harrison C, Perkins AC

    EJHaem 2025; (6(2)):e70007 doi:10.1002/jha2.70007.

    PMID: 40123795
  12. 12

    A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

    Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al.

    Haematologica 2015; (100(9)):1139-45 doi:10.3324/haematol.2014.119545.

    PMID: 26069290
  13. 13

    Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

    Harrison CN, Mesa R, Talpaz M, et al.

    The Lancet. Haematology 2024; (11(10)):e729-e740 doi:10.1016/S2352-3026(24)00212-6.

    PMID: 39265613
  14. 14

    Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.

    Sureau L, Orvain C, Ianotto JC, et al.

    Blood cancer journal 2021; (11(7)):135 doi:10.1038/s41408-021-00526-z.

    PMID: 34315858
  15. 15

    JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.

    Stein BL

    Leukemia & lymphoma 2023; (64(2)):292-299 doi:10.1080/10428194.2022.2136970.

    PMID: 36301740
  16. 16

    Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

    Gerds AT, Savona MR, Scott BL, et al.

    Blood advances 2020; (4(22)):5825-5835 doi:10.1182/bloodadvances.2020003314.

    PMID: 33232476
  17. 17

    Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.

    Gupta V, Oh S, Devos T, et al.

    Leukemia & lymphoma 2024; (65(7)):965-977 doi:10.1080/10428194.2024.2328800.

    PMID: 38501751
  18. 18

    Jaktinib and momelotinib for the treatment of myelofibrosis-Birds of a feather?

    Tefferi A

    American journal of hematology 2023; (98(10)):1517-1519 doi:10.1002/ajh.27036.

    PMID: 37471656

This page provides educational information about standard treatment strategies for MPNs. It is not a substitute for professional medical advice, so please consult your hematologist or MPN specialist regarding your specific care plan.

Get notified when new evidence is published on Myeloproliferative neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.